ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) is a Los Angeles-based clinical-stage company developing immune-based therapies for the treatment of brain and other cancers. The company has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. Other candidates in the ImmunoCellular pipeline include: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer killing T-cells. For more information, visit the company’s website at www.imuc.com